2021-22 Annual Report
Download PDF
SUCCESSFULLY CLEARED 15 US FDA INSPECTIONS.
Laying Strong Foundation1984 - 2003
Deepening Our Capabilities2004 - 2012
Increased Sustainable Growth2013 - Today
Incorporated
First API sale of Salbutamol Sulphate / Albuterol Sulphate
Neuland goes public
First US FDA Audit
USA Operation
Japan Subsidiary
R&D Centre established; EDQM Audit
PMDA, Japan Audit; First NCE Approval
Strategic alignment of business towards niche API & Custom Manufacturing Solutions
10th US FDA Audit
R&D Facility approved by US FDA
Among first 3 API facilities in India audited by CFDA
Acquisition of advanced intermediates & API Facility
Increased flow of projects from CMS Japan. Active emphasis on supply chain de-risking
100 Mn+ Revenue over 75 live CMS projects, 15th US FDA Audit
Unit – 3 Commercialisation 271 KL Reaction volume
Unit - 3 ANVISA Approval
Unit-1 InspectionMarch 1997, May 2004, March 2008 (PAI for NDA), November 2010, April 2014, April 2017, June 2019
Unit-2 InspectionJune 1999, February 2002, November 2005, September 2012, August 2015, November 2018, February 2020
Unit-1 InspectionDecember 2005
Unit-2 InspectionJune 2017
Unit-2 InspectionFebruary 2017
Unit-1 InspectionJanuary 2013
Unit-2 InspectionFebruary 2012
Unit-1 InspectionOctober 2008
Unit-2 InspectionOctober 2008
Unit-1 InspectionFebruary 2014
Unit-2 InspectionFebruary 2014
Unit-1 InspectionFeb. 2010, July 2014
Unit-1 InspectionJuly 2010, 2013
Unit-2 InspectionMay 2010, 2013
Unit-1 InspectionDecember 2017
Unit-1 InspectionAugust 2019
Unit-2 InspectionAugust 2019
Unit-2 InspectionApril 2011
Unit-1 InspectionMay 2017
Unit-1 InspectionMarch 2012, May 2014
Unit-2 InspectionApril 2011, May 2013
Unit-3 InspectionFebruary 2022
Unit-2 InspectionFebruary 2008